Teprotumumab and sensorineural hearing loss: a propensity score-matched retrospective cohort study

Teprotumumab and sensorineural hearing loss: a propensity score-matched retrospective cohort study

Teprotumumab, a monoclonal antibody that antagonizes the insulin-like growth factor 1 receptor, is the first medication within the United States to receive Food and Drug Administration (FDA) approval for thyroid eye disease (TED). The FDA recently issued a warning regarding otologic complications, s...

Full description

Saved in:
Bibliographic Details
Main Authors: Maxim John Levy Barnett, Justin Lam, Mikaela Nikkola Jara-Tantoco, Carlo Casipit, Sarah Eidbo, Catherine Anastasopoulou
Format: Article
Language:English
Published: Bioscientifica 2025-07-01
Series:Endocrine Connections
Subjects:
teprotumumab
sensorineural hearing loss
thyroid eye disease
graves’ ophthalmopathy
Online Access:https://ec.bioscientifica.com/view/journals/ec/14/7/EC-25-0293.xml
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items